[{"orgOrder":0,"company":"Bio Farma","sponsor":"Dr. Soetomo General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Bio Farma \/ Dr. Soetomo General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Bio Farma \/ Dr. Soetomo General Hospital"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"4-Valent HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bio Farma \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Bio Farma \/ Merck & Co"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Sinovac Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bio Farma \/ Bio Farma","highestDevelopmentStatusID":"15","companyTruncated":"Bio Farma \/ Bio Farma"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Hasan Sadikin General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Bio Farma \/ Hasan Sadikin General Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Hasan Sadikin General Hospital"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Indonesia University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Vi-Dt Typhoid Conjugate Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Bio Farma \/ Indonesia University","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Indonesia University"},{"orgOrder":0,"company":"Bio Farma","sponsor":"University of Indonesia | General University Hospital of Valencia | Andalas University | Hasanuddin University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bio Farma \/ University of Indonesia | General University Hospital of Valencia | Andalas University | Hasanuddin University","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ University of Indonesia | General University Hospital of Valencia | Andalas University | Hasanuddin University"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Universitas Padjadjaran | Udayana University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bio Farma \/ Universitas Padjadjaran | Udayana University","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ Universitas Padjadjaran | Udayana University"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Universitas Padjadjaran","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bio Farma \/ Universitas Padjadjaran","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ Universitas Padjadjaran"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Universitas Padjadjaran","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DTwP-HepB-Hib-IPV Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Bio Farma \/ Universitas Padjadjaran","highestDevelopmentStatusID":"7","companyTruncated":"Bio Farma \/ Universitas Padjadjaran"},{"orgOrder":0,"company":"Bio Farma","sponsor":"University of Indonesia | NIHRD, Ministry of Health, Indonesia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bio Farma \/ University of Indonesia | NIHRD, Ministry of Health, Indonesia","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ University of Indonesia | NIHRD, Ministry of Health, Indonesia"},{"orgOrder":0,"company":"Bio Farma","sponsor":"University of Indonesia | General University Hospital of Valencia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bio Farma \/ University of Indonesia | General University Hospital of Valencia","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ University of Indonesia | General University Hospital of Valencia"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Diphtheria Antitoxin","moa":"fluoroquinolone derivatives","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bio Farma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Bio Farma \/ Inapplicable"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Farma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Bio Farma \/ Inapplicable"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Universitas Padjadjaran | NIHRD, Ministry of Health, Indonesia | Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Universitas Padjadjaran | NIHRD, Ministry of Health, Indonesia | Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Universitas Padjadjaran | NIHRD, Ministry of Health, Indonesia | Sinovac Biotech"},{"orgOrder":0,"company":"Bio Farma","sponsor":"University of Indonesia | Diponegoro University | Andalas University | Hasanuddin University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ University of Indonesia | Diponegoro University | Andalas University | Hasanuddin University","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ University of Indonesia | Diponegoro University | Andalas University | Hasanuddin University"},{"orgOrder":0,"company":"Bio Farma","sponsor":"RS Umum Pusat Sanglah","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine","moa":"Surface antigen (HBsAg)","graph1":"Immunology","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ RS Umum Pusat Sanglah","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ RS Umum Pusat Sanglah"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Center for Child Health Universitas Gadjah Mada | Cipto Mangunkusumo Hospital\/Department of Child Health, Faculty of Medicine, University of Indonesia | General Hospital of Shenyang Military Region","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Center for Child Health Universitas Gadjah Mada | Cipto Mangunkusumo Hospital\/Department of Child Health, Faculty of Medicine, University of Indonesia | General Hospital of Shenyang Military Region","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Center for Child Health Universitas Gadjah Mada | Cipto Mangunkusumo Hospital\/Department of Child Health, Faculty of Medicine, University of Indonesia | General Hospital of Shenyang Military Region"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Bio Farma \/ Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Sinovac Biotech"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SARS-CoV-2 Subunit Recombinant Protein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio Farma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Bio Farma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          November 15, 2024

                          Lead Product(s) : DTwP-HepB-Hib-IPV Vaccine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Universitas Padjadjaran

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 02, 2023

                          Lead Product(s) : Enoxaparin Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 26, 2023

                          Lead Product(s) : Diphtheria Antitoxin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 06, 2023

                          Lead Product(s) : SARS-CoV-2 Subunit Recombinant Protein

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 14, 2023

                          Lead Product(s) : SARS-CoV-2 Protein Subunit Recombinant Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Universitas Padjadjaran

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Gardasil 4 (4-valent HPV vaccine) is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 13, 2022

                          Lead Product(s) : 4-Valent HPV Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : SARS-CoV-2 Protein Subunit Recombinant Vaccine

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Center for Child Health Universitas Gadjah Mada | Cipto Mangunkusumo Hospital/Department of Child Health, Faculty of Medicine, University of Indonesia | General Hospital of Shenyang Military Region

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          September 19, 2022

                          Lead Product(s) : SARS-CoV-2 Protein Subunit Recombinant Vaccine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Center for Child Health Universitas Gadjah Mada | Cipto Mangunkusumo Hospital/Department of Child Health, Faculty of Medicine, University of Indonesia | General Hospital of Shenyang Military Region

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : SARS-CoV-2 Protein Subunit Recombinant Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase II

                          Sponsor : Universitas Padjadjaran | Udayana University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          September 01, 2022

                          Lead Product(s) : SARS-CoV-2 Protein Subunit Recombinant Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Universitas Padjadjaran | Udayana University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Recombinant Hepatitis B Vaccine

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Hasan Sadikin General Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 01, 2022

                          Lead Product(s) : Recombinant Hepatitis B Vaccine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Hasan Sadikin General Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 01, 2022

                          Lead Product(s) : Hepatitis B Vaccine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : RS Umum Pusat Sanglah

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank